Cuorips

Cuorips Liabilities

The The Liabilities of Cuorips (4894.T) as of Nov 5, 2026 is 353.83 M JPY. In the previous year, The Liabilities was 211.91 M JPY — a change of 66.97% (higher).

Liabilities

353.83 MJPY

YoY

66.97%

Last updated:

In 2026, Cuorips's total liabilities amounted to 353.83 M JPY, a 66.97% difference from the 211.91 M JPY total liabilities in the previous year.

The Cuorips Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2021
141.95 M JPY
Jan 1, 2022
149.36 M JPY
Jan 1, 2023
133.79 M JPY
Jan 1, 2024
200.96 M JPY
Jan 1, 2025
211.91 M JPY
Jan 1, 2026
353.83 M JPY
The Cuorips Liabilities history
YEARLiabilitiesYoY
353.83 MJPY+66.97%
211.91 MJPY+5.45%
200.96 MJPY+50.20%
133.79 MJPY-10.42%
149.36 MJPY+5.22%
141.95 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cuorips Stock analysis

What does Cuorips do? Cuorips Inc generates revenue through regenerative medical products, primarily human iPS cell-derived cardiomyocyte sheets, and its CDMO business. The company develops these products in-house and through joint research with universities, research institutions, and major pharmaceutical companies. The CDMO services utilize CLiC-1, a commercial cell culture and processing facility with an integrated laboratory based on the Company's original design concept. Customers include major pharmaceutical companies and research institutions seeking regenerative medical solutions for the heart and other areas. The firm's regenerative medical products target heart conditions, developed through internal research and collaborations. The CDMO business provides contract development and manufacturing services using CLiC-1, serving pharmaceutical companies and research organizations. Revenue streams are derived from product sales and CDMO contracts, with the company focusing on heart-related applications and expanding into other medical areas through partnerships. Cuorips Inc's business model centers on leveraging its proprietary technology in iPS cell-derived cardiomyocyte sheets and CLiC-1 facility to serve pharmaceutical and research sectors. The company's products and services are designed for regenerative medicine applications, particularly for cardiac treatments, with sales and contracts driven by partnerships with major pharmaceutical companies and research institutions. Cuorips is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Cuorips's Liabilities

Cuorips's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Cuorips's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Cuorips's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Cuorips's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Cuorips’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Cuorips stock

The Liabilities of Cuorips is 353.83 M JPY in 2026.

The Liabilities of Cuorips changed from 211.91 M JPY to 353.83 M JPY, representing a 66.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Cuorips since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Cuorips historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cuorips

All Key Metrics — Cuorips